Onconova Therapeutics Announced Second Of Two Evaluable Participants In The Phase 2 Program Of Rigosertib Monotherapy In Advanced Squamous Cell Carcinoma Complicating Recessive Dystrophic Epidermolysis Bullosa Achieved A Complete Response Of All Cancerous

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!